EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

THREE BIOMARKERS TO EARLY DETECT COLORECTAL CANCER

*Mohammed Mutlaq Alanazi, Abdullah Bandar Almutairi and Nami M. Aljehani

ABSTRACT

Objective: Unusual methylation is one of the most frequent epigenetic modifications that can add to tumor development. Cell-free DNA can start from tumor tissue; in this manner, assessing methylation markers in cell-free DNA can be a promising strategy for malignancy screening. Our point was to find a strategy by comparing many studies to gather, to find promising biomarkers. Septin-9 gene (SEPT9), Syndecan-2 gene (SDC2) and Secreted frizzled-related protein 1 gene (SFRP1) are suitable biomarkers with different degrees of sensitivity and specificity for early detection of Colorectal cancer (CRC) by plasma sample. Materials and Methods: This literature review focuses on 2016 to 2020 for biomarkers and CRC early detection. Many websites were used, like PubMed, WHO, nature, and google scholar. The termers used in the research were marker or biomarker, SEPT9, Syndecan-2 gene (SDC2) and Secreted frizzled-related protein 1 gene (SFRP1) biomarkers, CRC diagnosis or screening, and colorectal or colon or rectal cancer. Many markers and methods have different sensitivity and specificity rates. Results: SEPT9, SDC2, and SFRP1 are promising biomarkers for the early detection of CRC. The combination of one or two biomarkers will increase the sensitivity and specificity detection rates. Conclusion: The outcomes from this review are that SEPT9, SDC2, and SFRP1 are promising biomarkers for detecting CRC. The combination between methylation biomarkers and traditional laboratory tests for CRC detection will increase the sensitivity and specificity. Our recommendation is to do these tests Epi pro Colon test, Colo Defense test, and Illumina human methylation test for CRC early detection in Saudi Arabia for patients from 30-40 years old and risk grope peoples. In this way, SEPT9, SDC2, and SEFR1 can turn into an incredible, for early CRC screening of high sensitivity and specificity.

Keywords: Septin-9 gene (SEPT9), Syndecan-2 gene (SDC2), Secreted frizzled-related protein 1 gene (SFRP1), Colorectal cancer (CRC).

[Full Text Article] [Download Certificate]